

Enanta Pharmaceuticals Inc

COMPANY AND PIPELINE OVERVIEW REPORT

A comprehensive coverage of the company and a summary of the drug pipeline portfolio.

Publication Date: 20-Jun-2013

THOMSON REUTERS

3 Times Square
New York, New York 10036
United States

Tel: +1 646 223 4000

thomsonreuters.com

[Return to Table of Contents](#)



ABOUT COMPANY AND PIPELINE OVERVIEW REPORT

Thomson Reuters provides the knowledge, tools, and expertise to help support drug discovery and development activities, IP portfolio optimization, identification of licensing and partnering opportunities, delivery of successful regulatory submissions, and the ability to keep current with the rapidly-changing pharmaceutical and chemical markets, supporting informed, early decisions.

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information. From drug discovery and development activities to patent reports, the latest deals, and partnering opportunities, *Cortellis* can provide the confidence to make the most informed business decisions, faster. *Cortellis for Competitive Intelligence* provides accurate and validated information on pharmaceutical and biotechnology companies globally, their drug pipelines, deals, patents, and clinical trials, plus breaking industry news and conference coverage. All contained in one simple, highly intuitive research platform.

Cortellis Company and Pipeline Overview reports are the first in a series of reports that track pharmaceutical and biotechnology companies worldwide. Further report offerings planned to follow include: Company Detailed Pipeline and Company Competitive Landscape reports. All *Cortellis for Competitive Intelligence* content is subject to the most comprehensive editorial review process available, conducted by scientists, pharma professionals, regulatory experts, and generics specialists. Featuring timely drug pipeline information expertly uncovered and integrated from over 400 global meetings each year, you'll always be on top of the latest developments.

Chosen by leading life sciences companies, their executives and investors, *Cortellis for Competitive Intelligence* accelerates your deal-making and gives you timely insights on the development landscape.

Discover undiscovered opportunities in drug development and licensing faster with *Thomson Reuters Cortellis™ for Competitive Intelligence*

DISCLAIMER

The information contained in this report is based on sources believed to be correct but Thomson Reuters does not guarantee the accuracy, timeliness, or completeness of this information. Opinions, if any, are those held by the author of any individual report or article at the time of initial publication and do not necessarily reflect the views of Thomson Reuters.

Information in this report on companies is intended for reference use only, and does not constitute a recommendation to buy or sell any particular security or other investment and does not constitute an offer to buy from or sell to any particular investor. Any company or securities mentioned in this report may not be suitable for any particular investor, depending on that investor's financial position and needs.

[Return to Table of Contents](#)



GLOSSARY

Number of Drugs in Active Development

Number of drugs associated with the company or subsidiary that are currently in active development, i.e. the development status for the drug(s) is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

Number of Inactive Drugs

Number of drugs associated with the company or subsidiary that are currently classified as inactive, i.e. where the development status for the drug(s) is one of the following: No Development Reported, Discontinued, or Withdrawn.

Number of Patents as Owner

Number of patents associated with the company where the company is listed as owner; i.e. the relationship type (or way the patent refers to the company) is: Patent Assignee/Owner, Patent owner (not assignee), Licensee for development and marketing, Licensee – marketing only (Distributor), Patent assignee of family member, Inferred assignee.

Number of Patents as Third Party

Number of patents associated with the company where the company is listed as third party; i.e. the relationship type (or way the patent refers to the company) is: Patent assignee (not owner), Ex-Licensee for development and marketing, Ex-Licensee marketing only (Distributor), Customer of technology, Ex-Customer of technology, Patent opponent or infringer, Affiliate organization of inventor, Owner of underlying technology.

Patents summary table

This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

Number of Deals

A count of deals where the company or one of its subsidiaries is the primary company.

Key Indications

Displays top ten key indications for the company and its subsidiaries based on frequency (indications occurring with high and identical frequency are always included, and this may result in more than ten Key Indications being listed). Includes both indications associated with patents where the company is patent owner and indications associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

Key Target-based Actions

Displays top ten key target-based actions for the company and its subsidiaries based on frequency (actions occurring with high and identical frequency are always included, and this may result in more than ten Key Target-based Actions being listed). Includes both target-based actions associated with patents where the company patent owner and target-based actions associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended. A target-based action is one that is associated with a target.

Key Technologies

Displays top ten key technologies for the company and its subsidiaries based on frequency (technologies occurring with high and identical frequency are always included, and this may result in more than ten Key Technologies being listed). Includes both key technologies associated with patents where the company relationship is patent owner and key technologies associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

[Return to Table of Contents](#)



PLEASE NOTE: the financials section where present in the report includes: Share Information, Stock Performance chart (including the consensus recommendation), and Major Shareholders. Financial Performance presents graphical and tabular data on Worldwide Sales, Operating Income and Net Income over time, together with a Quarterly earnings update. Balance Sheet lists Assets, Liabilities and Stockholders Equity, and Forecasts includes: EPS Forecast and Other Forecasts. The data reported in all sections (except share information and major stock holders) are correct as of the publication date of the report (and not the download date). For share information and major stock holders the data is correct for the date shown with these sections

[Return to Table of Contents](#)



TABLE OF CONTENTS

Company Overview..... 7

Company Profile..... 7

Product Portfolio Summary..... 8

Product Portfolio Drugs..... 11

[Return to Table of Contents](#)

Enanta Pharmaceuticals Inc

COMPANY OVERVIEW

| | |
|--|--|
| Company Name | Enanta Pharmaceuticals Inc |
| Parent Company Name | Enanta Pharmaceuticals Inc |
| Website | http://www.enanta.com/ |
| Country | US |
| Number of Drugs in Active Development | 11 |
| Number of Inactive Drugs | 4 |
| Number of Patents as Owner | 158 |
| Number of Patents as Third Party | 0 |
| Number of Deals | 5 |
| Key Indications | Hepatitis C virus infection, Bacterial infection, Gram positive bacterium infection, Bacterial respiratory tract infection, Hepatitis B virus infection, Neisseria gonorrhoeae infection, HIV infection, Inflammatory disease, Cystic fibrosis, Viral infection |
| Key Target-based Actions | Hepatitis C virus NS3 protease inhibitor, Hepatitis C virus protein NS5A inhibitor, Hepatitis C virus NS5B polymerase inhibitor, Peptidylprolyl isomerase inhibitor, Flavivirus NS3 protease inhibitor, Hepatitis C virus NS2-NS3 protease inhibitor, Hepatitis C virus protease inhibitor |
| Key Technologies | Small molecule therapeutic, Antibiotic, Oral formulation, Prodrug, Intravenous formulation, Dermatological formulation, Inhalant formulation, Drug combination, Antibiotic resistance, Local formulation unspecified, Systemic formulation unspecified, Tablet formulation |

COMPANY PROFILE

SUMMARY

Enanta Pharmaceuticals is a drug discovery company specializing in the development of small molecule anti-infective agents, especially macrolide and ketolide antibiotics.

LICENSING AGREEMENTS

In March 2003, Enanta received a milestone payment from Chiron for the completion of the first phase of Enanta's research for the discovery and development of small molecule HCV therapeutics. In September 2002, Enanta signed an exclusive, joint collaboration with Chiron for the discovery and development of small molecule HCV therapeutics. Enanta was to apply its macrocyclic chemistry and medicinal chemistry expertise to design and synthesize compounds targeting enzymes involved in the replication of the virus. Chiron gave Enanta a non-exclusive license to its HCV patents and Enanta gave Chiron an exclusive worldwide license to compounds that were developed. Enanta was also to receive research funding, milestone payments and royalties, while Chiron was to be responsible for preclinical and clinical development, manufacturing and sales and marketing.

FINANCIAL

In March 2013, Enanta announced the pricing of its initial public offering of 4 million common stock shares at a price of US \$14 each. The shares traded on the NASDAQ Global Select Market under the symbol 'ENTA'. The underwriters were granted a 30-day option to buy up to an additional 0.6 million common stock shares to cover over-allotments. The offering was expected to close on March 26, 2013; later that month, the offering was closed.

In November 2012, Enanta filed a registration statement with the U.S. Securities and Exchange Commission for proposed initial public offering of its common stock.

In August 2004, Enanta raised \$20 million in new financing, including contributions from Shionogi & Co Ltd, in order to advance its bridged bicyclic ketolide, EP-013420, into phase I trials, and to progress the company's discovery-stage anti-infective programs.

[Return to Table of Contents](#)



In January 2004, Enanta raised \$12 million in financing to advance its lead macrolide antibiotic program into clinical trials.

In June 2002, raised \$18 million in a private financing.


In 1999, Enanta raised \$5.1 million of equity financing and in July 2000, received \$20 million in a second round of private financing.

PRODUCT PORTFOLIO SUMMARY

DRUGS

Drugs by Indication

Active Drugs by Indication Chart




Drugs by Indication Table

| Indication | Active | Inactive | Total |
|--------------------------|--------|----------|-------|
| Infectious disease | 11 | 3 | 14 |
| Gastrointestinal disease | 6 | 2 | 8 |
| Inflammatory disease | 6 | 2 | 8 |
| Respiratory disease | 1 | 2 | 3 |
| Immune disorder | 0 | 1 | 1 |
| Dermatological disease | 0 | 1 | 1 |

[Return to Table of Contents](#)

Drugs by Highest Status

Active Drugs by Highest Status Chart



Drugs by Highest Status Table

| Development Status | Number of Drugs |
|-------------------------|-----------------|
| Phase 3 Clinical | 1 |
| Phase 2 Clinical | 1 |
| Phase 1 Clinical | 1 |
| Discovery | 7 |
| Suspended | 1 |
| Discontinued | 2 |
| No Development Reported | 2 |

DEALS

| Deal Type | Principal | | Partner | | Total |
|--|-----------|----------|---------|----------|-------|
| | Active | Inactive | Active | Inactive | |
| Drug - Funding | 1 | 0 | 0 | 0 | 1 |
| Drug - Development/Commercialization License | 3 | 0 | 1 | 0 | 4 |

CLINICAL TRIALS

[Return to Table of Contents](#)



Trials by Condition Studied

| Condition Studied | Ongoing | All |
|--------------------------|---------|-----|
| Infectious disease | 0 | 9 |
| Respiratory disease | 0 | 4 |
| Gastrointestinal disease | 0 | 2 |
| Inflammatory disease | 0 | 2 |
| Dermatological disease | 0 | 1 |

Trials by Phase

| Phase | Ongoing | All |
|---------|---------|-----|
| Phase 2 | 0 | 3 |
| Phase 1 | 0 | 6 |

Phase Definitions

Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

Phase 1 Clinical

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

PATENTS *

| Indication | As Owner | As Third Party | Total |
|--------------------------|----------|----------------|-------|
| Cardiovascular disease | 3 | 0 | 3 |
| Endocrine disease | 2 | 0 | 2 |
| Gastrointestinal disease | 118 | 0 | 118 |
| Genitourinary disease | 1 | 0 | 1 |
| Growth disorder | 2 | 0 | 2 |
| Degeneration | 2 | 0 | 2 |
| Immune disorder | 14 | 0 | 14 |
| Musculoskeletal disease | 9 | 0 | 9 |
| Neoplasm | 4 | 0 | 4 |
| Ocular disease | 3 | 0 | 3 |

[Return to Table of Contents](#)



| | | | |
|--------------------------------|-----|---|-----|
| Metabolic disorder | 3 | 0 | 3 |
| Mouth disease | 2 | 0 | 2 |
| Neurological disease | 2 | 0 | 2 |
| Respiratory disease | 38 | 0 | 38 |
| Infectious disease | 149 | 0 | 149 |
| Inflammatory disease | 121 | 0 | 121 |
| Otorhinolaryngological disease | 8 | 0 | 8 |
| Gynecology and obstetrics | 2 | 0 | 2 |
| Temperature disorder | 1 | 0 | 1 |
| Dermatological disease | 11 | 0 | 11 |
| Ulcer | 2 | 0 | 2 |
| Surgical procedure | 3 | 0 | 3 |

* This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

[Return to Table of Contents](#)

PRODUCT PORTFOLIO DRUGS

PLEASE NOTE: Highest status refers to highest development of that drug for one of the active companies

ABT-450 + ritonavir + ABT-267 (oral, HCV infection), AbbVie/Enanta

| | |
|-----------------------------|--|
| Drug Name | ABT-450 + ritonavir + ABT-267 (oral, HCV infection), AbbVie/Enanta |
| Key Synonyms | |
| Originator Company | Enanta Pharmaceuticals Inc |
| Active Companies | AbbVie Inc, Enanta Pharmaceuticals Inc |
| Inactive Companies | Abbott Laboratories |
| Highest Status | Phase 3 Clinical |
| Active Indications | Hepatitis C virus infection |
| Target-based Actions | Hepatitis C virus NS3 protease inhibitor, Hepatitis C virus protein NS5A inhibitor |
| Other Actions | Hepatitis C virus replication inhibitor |
| Technologies | Drug combination, Oral formulation, Tablet formulation, Small molecule therapeutic |
| Last Change Date | 18-Jun-2013 |

ABT-450

| | |
|-----------------------------|---|
| Drug Name | ABT-450 |
| Key Synonyms | |
| Originator Company | Chiron Corp |
| Active Companies | AbbVie Inc, Enanta Pharmaceuticals Inc |
| Inactive Companies | Abbott Laboratories, Chiron Corp |
| Highest Status | Phase 2 Clinical |
| Active Indications | Hepatitis C virus infection |
| Target-based Actions | Hepatitis C virus NS3 protease inhibitor |
| Other Actions | Hepatitis C virus replication inhibitor |
| Technologies | Oral formulation, Capsule formulation, Tablet formulation, Small molecule therapeutic |
| Last Change Date | 10-May-2013 |

[Return to Table of Contents](#)



next generation HCV protease inhibitor, AbbVie/Enanta

| | |
|-----------------------------|--|
| Drug Name | next generation HCV protease inhibitor, AbbVie/Enanta |
| Key Synonyms | |
| Originator Company | AbbVie Inc |
| Active Companies | AbbVie Inc, Enanta Pharmaceuticals Inc |
| Inactive Companies | |
| Highest Status | Phase 1 Clinical |
| Active Indications | Hepatitis C virus infection |
| Target-based Actions | Hepatitis C virus protease inhibitor |
| Other Actions | |
| Technologies | Systemic formulation unspecified, Small molecule therapeutic |
| Last Change Date | 09-Mar-2013 |

modithromycin

| | |
|-----------------------------|--|
| Drug Name | modithromycin |
| Key Synonyms | modithromycin |
| Originator Company | Enanta Pharmaceuticals Inc |
| Active Companies | Enanta Pharmaceuticals Inc |
| Inactive Companies | Shionogi & Co Ltd |
| Highest Status | Discovery |
| Active Indications | Neisseria gonorrhoeae infection |
| Target-based Actions | |
| Other Actions | Macrolide antibiotic |
| Technologies | Oral formulation, Small molecule therapeutic |
| Last Change Date | 18-Sep-2012 |

[Return to Table of Contents](#)

HCV polymerase inhibitors, Enanta

| | |
|-----------------------------|---|
| Drug Name | HCV polymerase inhibitors, Enanta |
| Key Synonyms | |
| Originator Company | Enanta Pharmaceuticals Inc |
| Active Companies | Enanta Pharmaceuticals Inc |
| Inactive Companies | |
| Highest Status | Discovery |
| Active Indications | Hepatitis C virus infection |
| Target-based Actions | Hepatitis C virus NS5B polymerase inhibitor |
| Other Actions | |
| Technologies | Small molecule therapeutic |
| Last Change Date | 26-Apr-2012 |

HCV cyclophilin binders/replication inhibitors, Enanta

| | |
|-----------------------------|--|
| Drug Name | HCV cyclophilin binders/replication inhibitors, Enanta |
| Key Synonyms | |
| Originator Company | Enanta Pharmaceuticals Inc |
| Active Companies | Enanta Pharmaceuticals Inc |
| Inactive Companies | |
| Highest Status | Discovery |
| Active Indications | Hepatitis C virus infection |
| Target-based Actions | Peptidylprolyl isomerase inhibitor |
| Other Actions | Hepatitis C virus replication inhibitor |
| Technologies | Small molecule therapeutic |
| Last Change Date | 04-May-2013 |

[Return to Table of Contents](#)

bicyclolide antibiotics (respiratory tract infection), Enanta

| | |
|-----------------------------|---|
| Drug Name | bicyclolide antibiotics (respiratory tract infection), Enanta |
| Key Synonyms | |
| Originator Company | Enanta Pharmaceuticals Inc |
| Active Companies | Enanta Pharmaceuticals Inc |
| Inactive Companies | |
| Highest Status | Discovery |
| Active Indications | Bacterial respiratory tract infection |
| Target-based Actions | |
| Other Actions | Macrolide antibiotic |
| Technologies | Antibiotic, Small molecule therapeutic |
| Last Change Date | 31-Oct-2012 |

EDP-788 (oral prodrug, bacterial infections), Enanta

| | |
|-----------------------------|---|
| Drug Name | EDP-788 (oral prodrug, bacterial infections), Enanta |
| Key Synonyms | |
| Originator Company | Enanta Pharmaceuticals Inc |
| Active Companies | Enanta Pharmaceuticals Inc |
| Inactive Companies | |
| Highest Status | Discovery |
| Active Indications | Bacterial infection |
| Target-based Actions | |
| Other Actions | Macrolide antibiotic |
| Technologies | Prodrug, Oral formulation, Antibiotic, Small molecule therapeutic |
| Last Change Date | 08-Feb-2013 |

[Return to Table of Contents](#)

EDP-788 (iv prodrug, bacterial infections), Enanta Pharmaceuticals

| | |
|-----------------------------|--|
| Drug Name | EDP-788 (iv prodrug, bacterial infections), Enanta Pharmaceuticals |
| Key Synonyms | |
| Originator Company | Enanta Pharmaceuticals Inc |
| Active Companies | Enanta Pharmaceuticals Inc |
| Inactive Companies | |
| Highest Status | Discovery |
| Active Indications | Bacterial infection |
| Target-based Actions | |
| Other Actions | Macrolide antibiotic |
| Technologies | Prodrug, Intravenous formulation, Antibiotic, Small molecule therapeutic |
| Last Change Date | 12-Feb-2013 |

NS5B nucleotide polymerase inhibitors (HCV infection), Enanta

| | |
|-----------------------------|---|
| Drug Name | NS5B nucleotide polymerase inhibitors (HCV infection), Enanta |
| Key Synonyms | |
| Originator Company | Enanta Pharmaceuticals Inc |
| Active Companies | Enanta Pharmaceuticals Inc |
| Inactive Companies | |
| Highest Status | Discovery |
| Active Indications | Hepatitis C virus infection |
| Target-based Actions | Hepatitis C virus NS5B polymerase inhibitor |
| Other Actions | |
| Technologies | Small molecule therapeutic |
| Last Change Date | 08-Feb-2013 |

[Return to Table of Contents](#)



EDP-322

| | |
|-----------------------------|--|
| Drug Name | EDP-322 |
| Key Synonyms | |
| Originator Company | Enanta Pharmaceuticals Inc |
| Active Companies | Enanta Pharmaceuticals Inc |
| Inactive Companies | |
| Highest Status | Suspended |
| Active Indications | Gram positive bacterium infection |
| Target-based Actions | |
| Other Actions | Macrolide antibiotic |
| Technologies | Oral formulation, Antibiotic, Small molecule therapeutic |
| Last Change Date | 31-Oct-2012 |

[Return to Table of Contents](#)

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information.

For more information about *Cortellis for Competitive Intelligence*, visit:

http://cortellis.thomsonreuters.com/cortellis_for_you/?cid=thomsonone.

For subscription information, e-mail scientific.lifesciences@thomsonreuters.com.

© 2012 Thomson Reuters. All rights reserved.
Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks and trademarks of Thomson Reuters and its affiliated companies.

[Return to Table of Contents](#)

